Hurler syndrome (HS) is an autosomal recessive, inherited metabolic storage disorder due to deficiency of lysosomal alpha-l-iduronidase (IDU) enzyme activity. ler patients requires further investigation, a timely second HCT can be well-tolerated and beneficial.
Hurler syndrome (HS), an autosomal recessive disease, is characterized by deficiency of lysosomal alpha-l-iduronidase (IDU) enzyme activity that results in abnormal, systemic accumulation of glycosaminoglycans (GAGs) namely dermatan sulfate and heparan sulfate. Clinical manifestations include hepatosplenomegaly, cardiac disease with coronary insufficiency, airway compromise, vision and hearing impairment, severe skeletal abnormalities, progressive mental retardation, hydrocephalus and premature death with a median life span of approximately 5 years. [1] [2] [3] [4] [5] [6] Allogeneic hematopoietic cell transplantation (HCT) is the only proven therapy that can prolong survival and either reverse or stabilize disease manifestations. [7] [8] [9] [10] [11] [12] [13] [14] HCT is effective due to repopulation of recipient tissues by metabolically competent donor cells, including tissue macrophages 14 and non-neuronal cells in the central nervous system. 15 Donor-derived cells provide a continuous source of IDU, resulting in reversal or amelioration of many HS features. Worldwide experience with more than 200 HS children shows that HCT can ensure long-term survival, 7, 8, 10, 12, 16 stabilize cognitive function, 11, 13, 17 and prevent fatal cardio-pulmonary complications. 18, 19 However, HS patients undergoing HCT present several challenges including increased regimen-related toxicity (RRT) particularly GVHD and pulmonary complications, 10, 20 variable neurologic dysfunction after transplantation, [10] [11] [12] [13] 17, 20 and an increased incidence of graft failure, 8, 10, 12, 21, 22 usually with concomitant rapid autologous marrow reconstitution. In this scenario, a second HCT can achieve long-term survival, yet entails potential for severe RRT.
We present our complete single institution experience of 11 HS children who underwent second HCT and report that second HCT can be beneficial with favorable neuropsychological outcomes.
Patients and methods

Patients, donors and conditioning
This study includes all 11 HS patients undergoing a second related (REL) or unrelated (URD) HCT for graft failure at the University of Minnesota between 1985 and 2000. Graft failure was defined as less than 10% donor chimerism. Patients received high-dose chemotherapy with or without radiation (Table 1) , followed by marrow infusion. Donor bone marrow was either from a different source or same source. All four siblings received marrow from the same (sibling) donor as for the first HCT; of the seven URD for the first HCT, one was used again for the same recipient. Heterozygous carrier siblings were eligible. Unrelated bone marrow (BM) donors were identified through the National Marrow Donor Program following its procedures and policies. 23 
Engraftment
Donor-derived engraftment was first assessed 21 days after hematopoietic cell infusion. We performed semi-quantitative restriction fragment length polymorphism (RFLP) analysis of peripheral blood derived leukocytes on days 21, 60, 100, and 1 year to determine chimerism. Chimerism was defined as complete (у90%) or partial (10-89%). Peripheral blood leukocyte IDU activity (homozygous normal range, 39 ± 15 nmol/mg of protein/hour) was assayed at days 60, 100 and 1 year after HCT.
Prophylaxis and grading of GVHD
T lymphocyte depletion by elutriation 24 was performed for all donor bone marrows (five of the 11) infused commencing in 1995. Acute GVHD was diagnosed and graded according to Glucksberg et al. 25 Patients were considered evaluable for acute GVHD if they survived more than 28 days.
Survival
Vital status was ascertained on all patients on 15 December 2000. The date and cause of death was recorded for all non-survivors.
Neuropsychological testing
A battery of standardized neuropsychological tests was used to assess the child's developmental or intellectual level, adaptive behavior, academic readiness or performance, neuropsychological functioning in several domains, and emotional and social functioning. Baseline tests were performed prior to first and second HCT. Annual evaluations were initiated 1 year after HCT. The specific tests used in the battery changed with the age of the examinee. In this study, only results of developmental and intelligence tests are reported. Baseline Mental Developmental Indices (MDI) from the Bayley Scales of Infant Development (BSID) were calculated from normative tables prior to first and second HCT, except where noted. At follow-up, the children were administered tests appropriate for their age (eg BSID or Stanford Binet Intelligence Scale) and either MDI or Standard Age Scores (intelligence) were calculated. While BSID is a measure of infant development, it is the prevailing method for estimating later cognitive development in children functioning with an age equivalent of less than 2 years.
Statistical analysis
Survival was estimated by the method of Kaplan and Meier. 26 
Results
Patients and donors
Between 1985 and 2000, 11 children with Hurler syndrome (HS) received a second HCT at the University of Minnesota. Patient and donor characteristics are summarized (Table 1 ). Survivors have been followed for a median of 25 months (range, 60 days to 12 years; Table 2 ). The median age of these patients was 25 months (range, 16 to 45 months) at second HCT, with a median interval of 8 months (range, 4 to 18.5 months) between the two transplants. Bone marrow was used as the source of donor hematopoietic cells in all cases. Four of the related grafts were from HLA-identical siblings and one from a mismatched grandfather (four of six antigen match). Of six URD used, four were phenotypically matched at six of six HLA A, B, and DRB1 loci. Commencing in 1995, all donor grafts infused (n = 5) were T cell depleted, four of which were from URD. Three of the four sibling donors had carrier levels of IDU; all other donors showed normal levels of IDU enzyme activity. All recipients of sibling donor grafts received first and second HCT from the same donor. Among non-sibling grafts, six of seven donors were different for the second HCT. The conditioning therapy is shown (Table 1) .
Survival
Five Hurler patients are surviving a median of 25 months (range, 60 days to 12 years) after second HCT ( Table 2 ). The overall actuarial survival ( Figure 1 ) was 50% (95% CI, 27% to 93%) at 4 years. In all five, complete or high partial donor chimerism (ie 77% to 100%) was documented. Of the five survivors, only one received bone marrow from an HLA-identical sibling. Of the six children who died, five were transplanted before 1994. 
Engraftment and leukocyte IDU activity
Partial or complete donor-derived hematopoiesis was detected in 10 of the 11 patients ( Table 2 ). Assessment of engraftment at day 100 or later (n = 8), showed a median donor chimerism of 100% (range, 77% to 100%; Table 2 ). Of the three patients who survived less than 100 days, two showed complete donor chimerism for the duration of follow-up, and one child died 2 months after HCT without evidence of either donor-derived engraftment or autologous reconstitution. Median leukocyte IDU activity prior to the second HCT was 0.7 nmol/mg of protein/h (range, 0 to 2.8 nmol/mg of protein/h). Leukocyte IDU activity results were available on six recipients at 100 days post HCT or later. All showed detectable IDU activity with a median of 26.7 nmol/mg of protein/h (range, 15.7 to 56.6 nmol/mg of protein/h).
Regimen-related toxicity (RRT) and GVHD
Transplant outcomes are presented (Table 2 ). Five patients developed grade II to IV acute GVHD. All three with grade III to IV disease received unmodified grafts either from an URD (n = 2) or a mismatched related donor (n = 1). Six children died between 1 month and 13.8 years after HCT. Causes of early transplant-related mortality (TRM) included pneumonitis (n = 2) and disseminated fungal infection (n = 1). Three deaths occurred after 100 days. One child, who received an unmodified graft from the same HLA 5 of 6 match URD for the first and second HCT, succumbed to grade IV GVHD 9 months later. Another child, who engrafted with full donor chimerism from an URD, developed persistent low-grade fevers with mild polyserositis 4 months after HCT. Lip biopsy to evaluate for occult chronic GVHD was carried out under general anesthesia using a laryngeal mask airway (LMA). In the immediate post-operative period, however, the child developed upper airway obstruction. Despite prompt intervention and ventilation, severe respiratory decompensation resulted in significant hypoxic neurologic damage. Life support was withdrawn at parental request after 2 weeks.
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The lip biopsy did not reveal GVHD; a post-mortem examination was not performed. Finally, one patient died of progressive pulmonary fibrosis almost 14 years after the second transplant. She had no evidence of chronic GVHD. Her conditioning regimen contained TBI for the first HCT and busulfan for the second HCT.
Neuropsychological function
Follow-up neuropsychological testing was performed 1 year after HCT and annually thereafter. Five patients have had follow-up evaluations from 1 to 9.5 years after second HCT (Table 3) . Two children (UPN 2802 and UPN 2848), one of whom had a BSID score of 74 prior to second HCT (UPN 2848), and the other a Stanford Binet IQ of 101 (UPN 2802), showed no further intellectual deterioration 1 year after HCT. One of these, UPN 2802, received the successful transplant at 34 months of age. Of the remaining three, one (UPN 793) suffered a bilateral stroke during a minor surgical procedure a few months before the second HCT and was left significantly impaired. There was additional intellectual deterioration after a successful second HCT. He is now 14 years of age. Testing showed his current intellectual abilities to be in the moderately retarded range, but stable. Another child (UPN 2072) whose MDI score was 85, received the second graft at 23 months of age and also demonstrated initial neuropsychological decline but subsequent stabilization (Table 3) . Finally, UPN 330, who died almost 14 years after second HCT from progressive pulmonary fibrosis, attended school and remained independent in all activities of daily living until a few months before her death. When last evaluated for IQ 9.5 years after HCT, she had a score of 80.
Discussion
Currently, HCT provides the only prospect for long-term survival with preserved intellectual function in children with HS. [8] [9] [10] [11] [12] [13] 16, 17, 20 However, HCT in these children is associated with a high incidence of graft failure. 8, 10, 12, 21, 22 We present our complete experience with second HCT in Hur- ler patients and report that long-term survival with favorable neuropsychological function is possible. Most reports of second HCT describe patients with hematological malignancies. Increased TRM, particularly venoocclusive disease and interstitial pneumonitis, independent of relapse mortality was observed with second HCT. [27] [28] [29] Some studies have recommended that patients undergo second HCT not less than 6 to 12 months following first HCT. 27, 28 However, continuing decline in intellectual function over time for HS children, necessitates timely HCT. The typical HS child begins life with normal mental ability, but shows a steady decline of two standard deviations in intelligence by 2 years of age. 11, 13 It is suggested that HS children receive HCT while their MDI exceeds 70. 10, 12 The median interval between the two transplants was 8 months in our study. Five children had an interval of less than 6 months; three of these patients have died, one each from engraftment failure, disseminated fungal infection, and severe GVHD. Three of six children who underwent HCT more than 6 months after the first conditioning regimen are alive. These results are comparable. Some recent studies suggest that young patient age and better supportive care (in more recent years) are stronger predictors of survival than the interval between the two HCT. 30, 31 While the median age of patients in our study was 25 months, their survival may have been more significantly influenced by the year of transplant. Eighty percent of children (four of five) transplanted after 1994 survived compared with only 17% (one of six) receiving HCT before 1994. The last five patients undergoing second HCT (after 1994) also received T cell-depleted grafts. The number of patients in this study is too small to attach statistical significance to these results; however, the improved outcome observed in recent years may be a combination of better supportive care, the use of T cell-depleted grafts, and advances in techniques of HLA typing and matching URD. Considering the critical need for timeliness of HCT in these patients, [10] [11] [12] [13] at our institution, we now propose second HCT in HS children as early as 5 to 6 months after a failed first transplant.
Second HCTs in both malignant and non-malignant disorders have been performed using either the same, or a different donor. [32] [33] [34] [35] In our study, five of 11 HS children received a second HCT from the same marrow donor (matched sibling, four of four; URD, one of seven). Overall, 10 of 11 patients showed donor engraftment. These results are in contrast with the high incidence of graft failure with first HCT in Hurler children. From 1983 to 2000, 71 Hurler children received a first HCT at our institution; 19 (27%), showed graft failure (unpublished data). Other groups and collaborative reports cite similar experiences. 8, 10, 12, 21, 22 Improved donor engraftment following second HCT maybe attributable to a more immunosuppressed host, less marrow reserve, and/or GAG clearance following transient donor engraftment after first HCT.
Children with HS are at risk of greater peri-operative morbidity, [36] [37] [38] due to difficult airway visualization, excessive secretions, need for emergency tracheotomy, odontoid hypoplasia with risk of spinal cord morbidity, and higher incidence of post-extubation obstruction. Intra-operative cardiac arrest due to coronary artery disease has also been described. 36, 38 In our study, two patients had peri-operative complications. One patient (UPN 793) developed a bilateral watershed area stroke during minor surgery under general anesthesia. Another child, who underwent general anesthesia using LMA, developed acute upper airway obstruction in the immediate post-operative period and a clinical picture consistent with severe post-obstructive pulmonary edema. This suggests that even with optimal care, these patients who have low reserve are at an increased risk during anesthesia and surgery. The goals of therapy for HS children include long-term survival with a positive quality of life. 11, 13 In our study, five children were evaluable for neuropsychological testing after second HCT. Despite sustained donor-derived engraftment, two children (UPN 793 and 2072) showed initial decline in mental ability after second HCT. UPN 2072, did not have an obvious etiology to explain the initial intellectual decline. Suggested predictors of adverse neuropsychological outcome after HCT include age Ͼ2 years, MDI Ͻ70 at HCT, and post-transplant morbidity including GVHD. [10] [11] [12] [13] This child received the second HCT at 23 months of age when his MDI score was 85. No obvious post-transplant morbidity was present; despite achieving complete donor chimerism, he continued to show initial regression on formal neuropsychologic testing. However, inspection of his test results demonstrated that while he was acquiring skills at a slower than expected rate, he did not lose any acquired skills. Interestingly, both UPN 793 and 2072, while functioning below the expected average for age, have stabilized their intellectual function and are 14 and 8 years of age. Two patients stabilized neurocognitively 1 year after second transplant (Table 3) ; this contrasts with the natural history of HS. 13, 16 Another child (UPN 330) lived to 17 years of age, attended school, was independent in daily activities, and showed stable mental ability slightly below the normal range. These data suggest that for HS children who experience graft failure, a successful second HCT can result in stable mental abilities, although perhaps with a slower than expected rate of development. It should also be noted that prior to 1998, the intensity of rehabilitation and educational services was not optimal for most HS patients. Recently, we have learned that intensive, continuous language stimulation as well as occupational and physical therapy, led by a team of experienced professionals, are critical components in optimizing cognitive development and quality of life for HS children.
Explanations for the higher incidence of engraftment failure in HS continue to be pursued. Hypotheses include relatively normal immune function, an abnormal bone marrow microenvironment, radiation-and chemotherapy-resistant stem cells, 11 and higher busulfan clearance, 39 although the latter appears less likely in view of our recent work. 40 With a better understanding of these mechanisms, the percentage of children engrafting with their first transplant should improve. Meanwhile, a significant minority of children with HS will need a second transplant to correct their enzyme deficiency. Our study showed that a second transplant in Hurler children can be well tolerated and can lead to stable neuropsychological function.
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